T-cell subsets in scleroderma patients

Systemic sclerosis (SSc), or scleroderma, is characterized by fibrosis of the skin and internal organs, vascular abnormalities and alterations of the immune response compartment. T cells are present in affected tissues, including the skin, early in the disease course, appear to be oligoclonal, indicating an antigen-driven process, and preferentially produce Th2 cytokines, including IL-4 and IL-13, which may directly favor excessive extracellular matrix deposition. Th1 cells may also be present. Initial determinations indicate that Th17 numbers are increased and T cells with regulatory functions are defective. Of interest, genetic association studies have preferentially identified polymorphisms of genes coding for molecules belonging to the immune system as risk factors for SSc development, further stressing the importance of immune dysregulation in SSc pathobiology. While current therapeutic approaches remain disappointing, we discuss the advance in our understanding of the immune abnormalities characteri...

[1]  S. Gay,et al.  The controversial role of tumor necrosis factor alpha in fibrotic diseases. , 2008, Arthritis and rheumatism.

[2]  C. De Simone,et al.  Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea , 2010, The British journal of dermatology.

[3]  J. Dayer,et al.  Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. , 2003, Arthritis and rheumatism.

[4]  T. Medsger,et al.  Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. , 2003, Arthritis and rheumatism.

[5]  T. Medsger,et al.  Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. , 2009, Arthritis and rheumatism.

[6]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[7]  R. Corrocher,et al.  Antibodies against Human Cytomegalovirus in the Pathogenesis of Systemic Sclerosis: A Gene Array Approach , 2005, PLoS medicine.

[8]  A. del Rosso,et al.  Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations , 2004, Annals of the rheumatic diseases.

[9]  Lisa M. Ebert,et al.  A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells , 2004, The Journal of experimental medicine.

[10]  H. Spits,et al.  Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.

[11]  A. Fietta,et al.  Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. , 2009, Clinical and experimental rheumatology.

[12]  I. Fajardy,et al.  STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. , 2009, Arthritis and rheumatism.

[13]  A. Wells,et al.  Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial? , 2007, American journal of respiratory and critical care medicine.

[14]  D. Elewaut,et al.  Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study , 2008, Annals of the rheumatic diseases.

[15]  T. Krieg,et al.  Skin disease: a cardinal feature of systemic sclerosis. , 2006, Rheumatology.

[16]  K. Sullivan,et al.  Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. , 2006, Arthritis and rheumatism.

[17]  T. Ohtsuka Effect of γδ T cell supernatant on human skin fibroblast proliferation and collagen production – Possible role of transforming growth factor‐β and basic fibroblast growth factor , 2008, International journal of dermatology.

[18]  R. Wise,et al.  Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. , 1999, Arthritis and rheumatism.

[19]  B. Granel,et al.  Implication de l'interleukine 13 et de son récepteur dans la sclérodermie systémique , 2007 .

[20]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.

[21]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.

[22]  U. Müller-Ladner,et al.  Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database , 2008, Annals of the rheumatic diseases.

[23]  C. Denton,et al.  Disease-modifying treatment in systemic sclerosis: current status , 2009, Current opinion in rheumatology.

[24]  P. Dieudé,et al.  Genetic background of systemic sclerosis: autoimmune genes take centre stage. , 2010, Rheumatology.

[25]  M. Di Franco,et al.  Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease , 1997, Clinical and experimental immunology.

[26]  E. Hofny,et al.  Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1β, and tumour necrosis factor α in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis , 2005, Journal of Clinical Pathology.

[27]  M. Piccinni,et al.  Microchimerism and Systemic Sclerosis , 2001, International Archives of Allergy and Immunology.

[28]  M. Kahaleh,et al.  γδ Receptor Bearing T Cells in Scleroderma: Enhanced Interaction with Vascular Endothelial Cellsin Vitro , 1999 .

[29]  Y. Hamaguchi Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis , 2010, The Journal of dermatology.

[30]  D. Abraham,et al.  Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma , 2007, Nature Clinical Practice Rheumatology.

[31]  Zhanju Liu,et al.  Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. , 2009, World journal of gastroenterology.

[32]  S. Durham,et al.  Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. , 2009, The Journal of clinical investigation.

[33]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[34]  A. Wells,et al.  Pulmonary complications: one of the most challenging complications of systemic sclerosis. , 2006, Rheumatology.

[35]  J. Varga Systemic sclerosis: an update. , 2008, Bulletin of the NYU hospital for joint diseases.

[36]  U. Müller-Ladner,et al.  Renal complications and scleroderma renal crisis. , 2006, Rheumatology.

[37]  D. Alarcón-Segovia,et al.  Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients. , 1995, Clinical and experimental rheumatology.

[38]  M. Fujimoto,et al.  Increased serum interleukin 23 in patients with systemic sclerosis. , 2008, The Journal of rheumatology.

[39]  G. Pizzolo,et al.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. , 1997, The American journal of pathology.

[40]  T. Flotte,et al.  Interferons and collagen production. , 1990, The Journal of investigative dermatology.

[41]  G. Damonte,et al.  Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells , 2000, Nature Medicine.

[42]  R. Clark Skin-resident T cells: the ups and downs of on site immunity. , 2010, The Journal of investigative dermatology.

[43]  Francesco Boin,et al.  T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. , 2008, Arthritis and rheumatism.

[44]  M. Mayes,et al.  Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. , 2001, Arthritis and rheumatism.

[45]  R. Lafyatis,et al.  The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes , 2009, PloS one.

[46]  P. Merkel,et al.  B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. , 2009, Arthritis and rheumatism.

[47]  A. Santoni,et al.  Soluble interleukin‐2 receptor, interleukin‐2 and interleukin‐4 in sera and supernatants from patients with progressive systemic sclerosis , 1990, Clinical and experimental immunology.

[48]  U. Müller-Ladner,et al.  Mechanisms of vascular damage in systemic sclerosis , 2009, Autoimmunity.

[49]  Annette Lee,et al.  Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus , 2010, Nature Genetics.

[50]  M. Matucci-Cerinic,et al.  Circulating γ/δ T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization , 2001 .

[51]  D. Fox,et al.  The role of T helper type 17 cells in inflammatory arthritis , 2010, Clinical and experimental immunology.

[52]  M. Aurrand-Lions,et al.  Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. , 2007, Arthritis and rheumatism.

[53]  M. Gruschwitz,et al.  Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. , 1997, Arthritis and rheumatism.

[54]  M. Fujimoto,et al.  Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. , 2009, Arthritis and rheumatism.

[55]  D. Artis,et al.  Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A , 2010, The Journal of experimental medicine.

[56]  F. Annunziato,et al.  Heterogeneity of human effector CD4+ T cells , 2009, Arthritis research & therapy.

[57]  J. Reveille,et al.  Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. , 1996, Arthritis and rheumatism.

[58]  V. Pascual,et al.  Systemic sclerosis and lupus: points in an interferon-mediated continuum. , 2010, Arthritis and rheumatism.

[59]  T. Krieg,et al.  Localization of collagen mRNA in normal and scleroderma skin by in‐situ hybridization , 1988, European journal of clinical investigation.

[60]  N. Bellamy,et al.  A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. , 2001, Arthritis and rheumatism.

[61]  T. Whiteside,et al.  Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis , 1990, Clinical and experimental immunology.

[62]  A. Wald,et al.  Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation , 2007, The Journal of experimental medicine.

[63]  O. Distler,et al.  Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies , 2009, Annals of the rheumatic diseases.

[64]  M. Fujimoto,et al.  Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? , 2008, Journal of dermatological science.

[65]  Leroy Ec,et al.  Autoimmunity and Vascular Involvement in Systemic Sclerosis (SSc) , 1999 .

[66]  M. Hasegawa,et al.  Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. , 2000, The Journal of rheumatology.

[67]  J. Dayer,et al.  Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts , 2005, Arthritis research & therapy.

[68]  M. Mayes,et al.  Extended Report , 2022 .

[69]  C. Clavel,et al.  Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. , 1996, Archives of dermatology.

[70]  J. Reveille,et al.  The genetics of scleroderma (systemic sclerosis) , 2010, Current opinion in rheumatology.

[71]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[72]  J. Rosenbloom,et al.  Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies , 2010, Annals of Internal Medicine.

[73]  M. Matucci-Cerinic,et al.  Circulating Vδ1 + T cells are activated and accumulate in the skin of systemic sclerosis patients , 1998 .

[74]  F. Sampogna,et al.  a4b1+ and a4b7+ CD4+ T cell numbers increase and CLA+ CD4+ T cell numbers decrease in systemic sclerosis , 2005 .

[75]  C. Boileau,et al.  Genetic basis for systemic sclerosis. , 2007, Joint, bone, spine : revue du rhumatisme.

[76]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[77]  K. Stengaard-Pedersen,et al.  Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. , 1998, British journal of rheumatology.

[78]  W. Paul,et al.  Heterogeneity and plasticity of T helper cells , 2010, Cell Research.

[79]  H. Oberg,et al.  Innate immune functions of human gammadelta T cells. , 2008, Immunobiology.

[80]  K. Esposito,et al.  Peripheral Blood T Lymphocytes from Systemic Sclerosis Patients Show Both Th1 and Th2 Activation , 2001, Journal of Clinical Immunology.

[81]  Increased Frequency and Compromised Function of T Regulatory Cells in Systemic Sclerosis (SSc) Is Related to a Diminished CD69 and TGFβ Expression , 2009, PloS one.

[82]  S. Carding,et al.  γδ T cells: functional plasticity and heterogeneity , 2002, Nature Reviews Immunology.

[83]  I. Douglas,et al.  Regulatory Role of γδ T Cells in the Recruitment of CD4+ and CD8+ T Cells to Lung and Subsequent Pulmonary Fibrosis1 , 2006, The Journal of Immunology.

[84]  K. Takabayashi,et al.  Increased interleukin-17 production in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[85]  M. Fujimoto,et al.  Increased Serum Soluble OX40 in Patients with Systemic Sclerosis , 2008, The Journal of Rheumatology.

[86]  S. Shete,et al.  Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. , 2009, Arthritis and rheumatism.

[87]  C. Clavel,et al.  Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. , 1992, European journal of cell biology.

[88]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[89]  Brenda W Gillespie,et al.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. , 2003, Arthritis and rheumatism.

[90]  Michael J. Grusby,et al.  Enhanced Interleukin (IL)-13 Responses in Mice Lacking IL-13 Receptor α 2 , 2003, The Journal of experimental medicine.

[91]  B. White,et al.  The role of chemokines in the pathogenesis of scleroderma , 2003, Current opinion in rheumatology.

[92]  T. Wynn Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[93]  R. Wise,et al.  Expansion of selected V delta 1+ gamma delta T cells in systemic sclerosis patients. , 1994, Journal of immunology.

[94]  I. Fajardy,et al.  Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. , 2009, Arthritis and rheumatism.

[95]  L. Cosmi,et al.  Chemoattractant Receptors Expressed on Type 2 T Cells and Their Role in Disease , 2001, International Archives of Allergy and Immunology.

[96]  S. Shete,et al.  Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. , 2010, Journal of autoimmunity.

[97]  C. Verweij,et al.  Transcription profiling of rheumatic diseases , 2009, Arthritis research & therapy.

[98]  M. Mayes,et al.  BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians , 2009, Annals of the rheumatic diseases.

[99]  D. Abraham,et al.  Overview of pathogenesis of systemic sclerosis. , 2006, Rheumatology.

[100]  C. Meisel,et al.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients , 2009, Arthritis research & therapy.

[101]  É. Rich,et al.  Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival , 2002, Medicine.

[102]  D. Jarrossay,et al.  Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells , 2009, Nature Immunology.

[103]  K. Bost,et al.  Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts. , 1992, Clinical immunology and immunopathology.

[104]  H. Katai,et al.  Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. , 1992, The Journal of clinical investigation.

[105]  R. Scrivo,et al.  Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. , 2005, The Journal of rheumatology.

[106]  R. Clark,et al.  The Vast Majority of CLA+ T Cells Are Resident in Normal Skin1 , 2006, The Journal of Immunology.

[107]  Koichiro Nakamura,et al.  The role of lymphocytes in healthy and eczematous skin , 2001, Current opinion in allergy and clinical immunology.

[108]  F. Maquart,et al.  Antagonistic Effects of Interferon-γ and Interleukin-4 on Fibroblast Cultures. , 1997 .

[109]  D. Farge,et al.  In Vitro Evidence for a Direct Antifibrotic Role of the Immunosuppressive Drug Mycophenolate Mofetil , 2007, Journal of Pharmacology and Experimental Therapeutics.

[110]  F. Torricelli,et al.  Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. , 2002, Arthritis and rheumatism.

[111]  J. Sibilia,et al.  Incidence and prevalence of systemic sclerosis: a systematic literature review. , 2008, Seminars in arthritis and rheumatism.

[112]  T. Matsushita,et al.  Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. , 2006, The Journal of rheumatology.

[113]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[114]  P. Dieudé,et al.  The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. , 2008, Arthritis and rheumatism.

[115]  L. Settas,et al.  Early T cell activation in the skin from patients with systemic sclerosis , 2005, Annals of the rheumatic diseases.

[116]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[117]  S. Shete,et al.  Association of Interleukin 23 Receptor Polymorphisms with Anti-Topoisomerase-I Positivity and Pulmonary Hypertension in Systemic Sclerosis , 2009, The Journal of Rheumatology.

[118]  I. Bank,et al.  Vgamma9+ gammadelta T cells in systemic sclerosis patients are numerically and functionally preserved and induce fibroblast apoptosis. , 2010, Immunobiology.

[119]  A. Grassegger,et al.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis , 2007, Wiener Medizinische Wochenschrift.

[120]  J. Gaudart,et al.  IL13RA2 gene polymorphisms are associated with systemic sclerosis. , 2006, The Journal of rheumatology.

[121]  T. Wynn IL-13 effector functions. , 2003, Annual review of immunology.